# Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

> **NCT02106988** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **RADIATION:** Radiation Therapy
- **DRUG:** Dexamethasone
- **DRUG:** Etoposide phosphate
- **DRUG:** Ifosfamide
- **DRUG:** Mesna
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02106988
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-01-16
- **Primary completion:** 2034-01-31
- **Final completion:** 2034-01-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106988, "Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02106988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*